Acadia Pharmaceuticals | ACAD - Equity Capital And Reserves


Acadia Pharmaceuticals reported $917.27M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
ALKERMES USD 1.73B 108.85M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Corcept Therapeutics USD 631.9M 3.89M Sep/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Eisai JPY 854.43B 25.92B Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
J&J USD 78.47B 0 Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Prothena USD 294.99M 29.34M Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025